Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future (Q38299414)

1 September 2017

1 reference

title

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future (English)

1 reference

1 September 2017

0 references

6

Bruno Dubois

0 references

Shireen Sindi

object named as

Shireen Sindi

5

0 references

Miia Kivipelto

object named as

Miia Kivipelto

4

0 references

Harald Hampel

1

object named as

Harald Hampel

1 reference

1 September 2017

9

Paul S Aisen

1 reference

1 September 2017

8

Robert Nisticò

2 references

ORCID Public Data File 2021

1 September 2017

2

Lon S Schneider

1 reference

1 September 2017

Ezio Giacobini

3

1 reference

1 September 2017

Karl Broich

7

1 reference

1 September 2017

Simone Lista

10

1 reference

1 September 2017

publication date

24 December 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 September 2017

published in

1 reference

1 September 2017

volume

15

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

83-105

1 reference

The genetics of Alzheimer disease: back to the future

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Nature versus Nurture: Death of a Dogma, and the Road Ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Apolipoprotein E in Alzheimer's disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Genetic insights in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

New insights into the dementia epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Advances in the prevention of Alzheimer's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Targeting synaptic dysfunction in Alzheimer's disease therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Peptide inhibitors of beta amyloid aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Secretase inhibitors and modulators for Alzheimer's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Methylene blue and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Tau-aggregation inhibitor therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Progress in the development of new drugs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer disease as a vascular disorder: nosological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

'Clinical trials in Alzheimer's disease': immunotherapy approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Testing the right target and right drug at the right stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Regulatory innovation and drug development for early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Immunotherapy against amyloid pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A beta oligomers - a decade of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Preclinical Alzheimer disease-the challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer disease therapy--moving from amyloid-β to tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Therapeutic strategies for tau mediated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A feasibility and tolerability study of lithium in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

In vivo tau imaging: obstacles and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Down's syndrome and Alzheimer's disease: towards secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The A4 study: stopping AD before symptoms begin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer's disease research and development: a call for a new research roadmap

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

CSF biomarker variability in the Alzheimer's Association quality control program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The projected effect of risk factor reduction on Alzheimer's disease prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Risk factors and preventive interventions for Alzheimer disease: state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Dementia prevention: current epidemiological evidence and future perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer's disease market: hope deferred

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer's disease from researcher to caregiver: a personal journey and call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Between new genetic discoveries and large randomized trials--neurological research in the era of systems medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995637

Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer's disease

21 January 2018

1 reference

27 August 2024

https://opencitations.net/index/api/v1/citations/10.1186/GM204

Identifiers

DOI

10.1586/14737175.2015.995637

1 reference

1 September 2017

1 reference